Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ADG106 · 2 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| ADG106 Dose escalation | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ADG106 | DRUG | IV infusion over 60 minutes on Day 1 of each cycle, at 7 doses depending on cohort at enrollment. |
Inclusion Criteria: 1. Male or female, 18 years to 75 years of age at the time of consent. 2. Provide written informed consent. 3. Subjects with advanced and/or metastatic histologically or cytologically confirmed solid tumor and/or non-Hodgkin lymphoma who are refractory or relapsed from standard ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
ADG106 is an investigational small molecule being studied for the treatment of advanced or metastatic solid tumors and non-Hodgkin lymphoma. It is in Phase 1 clinical development and has not been approved by regulatory authorities.
ADG106 is being developed by Adagene Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol ADAG. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational oncology drug.
ADG106 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval and is still being studied in clinical trials to assess its safety and potential efficacy in patients.
ADG106 has been studied in two completed Phase 1 clinical trials. One trial, NCT03707093, was conducted in the United States and enrolled 49 patients with solid tumors or non-Hodgkin lymphoma. The other, NCT03802955, was conducted in China and enrolled 62 patients with the same conditions.
ADG106 is described as a CD137 agonist in the title of one of its clinical trials, NCT03707093. This indicates that the drug is designed to target and activate the CD137 receptor, which is involved in immune response regulation.